Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Aug;38(4):406-421.
doi: 10.1002/jca.22040. Epub 2023 Jan 13.

Concomitant pharmacologic medications influence the clinical outcomes of granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis: A multicenter retrospective cohort study

Nobuhiro Ueno  1 , Yuya Sugiyama  1 , Yu Kobayashi  1 , Yuki Murakami  1 , Takuya Iwama  2 , Takahiro Sasaki  1 , Takehito Kunogi  1 , Aki Sakatani  1 , Keitaro Takahashi  1 , Kazuyuki Tanaka  3 , Shinya Serikawa  4 , Katsuyoshi Ando  1 , Shin Kashima  1 , Momotaro Muto  5 , Yuhei Inaba  2 , Kentaro Moriichi  1 , Hiroki Tanabe  1 , Toshikatsu Okumura  1 , Mikihiro Fujiya  1
Affiliations
Multicenter Study

Concomitant pharmacologic medications influence the clinical outcomes of granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis: A multicenter retrospective cohort study

Nobuhiro Ueno et al. J Clin Apher. 2023 Aug.

Abstract

Background: Granulocyte and monocyte adsorptive apheresis (GMA) with Adacolumn has been used as a remission induction therapy for patients with active ulcerative colitis (UC). Herein, we investigated the influence of concomitant medications in the remission induction of GMA in patients with active UC.

Methods: This multicenter retrospective cohort study included patients with UC underwent GMA in five independent institutions in Japan from January 2011 to July 2021. Factors including concomitant medications associated with clinical remission (CR) were analyzed statistically.

Result: A total of 133 patients were included. Seventy-four patients achieved a CR after GMA. The multivariable analysis revealed that concomitant medication with 5-aminosalicylic acid, Mayo endoscopic subscore (MES), and concomitant medication with immunosuppressors (IMs) remained as predictors of CR after GMA. In the subgroup analysis in patients with MES of 2, concomitant medication with IMs was demonstrated as a significant negative factor of CR after GMA (P = .042, OR 0.354). Seventy-four patients who achieved CR after GMA were followed up for 52 weeks. In the multivariable analysis, the maintenance therapy with IMs was demonstrated as a significant positive factor of sustained CR up to 52 weeks (P = .038, OR 2.214). Furthermore, the rate of sustained CR in patients with biologics and IMs was significantly higher than that in patients with biologics only (P = .002).

Conclusion: GMA was more effective for patients with active UC that relapsed under treatment without IMs. Furthermore, the addition of IMs should be considered in patients on maintenance therapy with biologics after GMA.

Keywords: biologics; clinical remission; granulocyte and monocyte apheresis; immunosuppressors; loss of response; negative factor; positive factor; ulcerative colitis.

PubMed Disclaimer

References

REFERENCES

    1. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380(9853):1606-1619. doi:10.1016/S0140-6736(12)60150-0
    1. Hanai H, Takeda Y, Eberhardson M, et al. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163(1):50-58. doi:10.1111/j.1365-2249.2010.04279.x
    1. Hibi T, Sameshima Y, Sekiguchi Y, et al. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis. 2009;41(8):570-577. doi:10.1016/j.dld.2008.11.020
    1. Kruis W, Dignass A, Steinhagen-Thiessen E, et al. Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol. 2005;11(44):7001-7006. doi:10.3748/wjg.v11.i44.7001
    1. Passalacqua S, Ferraro PM, Bresci G, et al. The Italian registry of therapeutic apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease: a multicentric study. J Clin Apher. 2011;26(6):332-337. doi:10.1002/jca.20315

Publication types

Substances

LinkOut - more resources